Cargando…

Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial

IMPORTANCE: Faricimab neutralizes angiopoietin-2 and vascular endothelial growth factor A via both simultaneous and independent binding. OBJECTIVE: To evaluate extended dosing with faricimab, the first bispecific antibody designed for intraocular use, in patients with neovascular age-related macular...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khanani, Arshad M., Patel, Sunil S., Ferrone, Philip J., Osborne, Aaron, Sahni, Jayashree, Grzeschik, Susanna, Basu, Karen, Ehrlich, Jason S., Haskova, Zdenka, Dugel, Pravin U.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2020
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7489851/ https://www.ncbi.nlm.nih.gov/pubmed/32729897 http://dx.doi.org/10.1001/jamaophthalmol.2020.2699

Ejemplares similares

Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial
por: Sahni, Jayashree, et al.
Publicado: (2020)

TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration
por: Khanani, Arshad M., et al.
Publicado: (2021)

Predictors of Early Diabetic Retinopathy Regression with Ranibizumab in the RIDE and RISE Clinical Trials
por: Singer, Michael, et al.
Publicado: (2020)

Faricimab for Diabetic Macular Edema in Patients Refractory to Ranibizumab or Aflibercept
por: Ohara, Hiromi, et al.
Publicado: (2023)

Targeting Angiopoietin in Retinal Vascular Diseases: A Literature Review and Summary of Clinical Trials Involving Faricimab
por: Khan, Majid, et al.
Publicado: (2020)

The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study – 6 month results
por: Khanani, Arshad M., et al.
Publicado: (2023)

Intravitreal Faricimab for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
por: Rush, Ryan B, et al.
Publicado: (2022)

Stairway to the mind : the controversial new science of consciousness /
por: Scott, Alwyn, 1931-
Publicado: (1995)

YOSEMITE and RHINE: Phase 3 Randomized Clinical Trials of Faricimab for Diabetic Macular Edema: Study Design and Rationale
por: Eter, Nicole, et al.
Publicado: (2021)

BALATON and COMINO: Phase III Randomized Clinical Trials of Faricimab for Retinal Vein Occlusion: Study Design and Rationale
por: Hattenbach, Lars-Olof, et al.
Publicado: (2023)

Machine Learning to Predict Response to Ranibizumab in Neovascular Age-Related Macular Degeneration
por: Maunz, Andreas, et al.
Publicado: (2023)

Faricimab for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
por: Ferro Desideri, Lorenzo, et al.
Publicado: (2023)

Machine Learning to Predict Faricimab Treatment Outcome in Neovascular Age-Related Macular Degeneration
por: Kikuchi, Yusuke, et al.
Publicado: (2023)

Escaleras stairways: enciclopedias de diseño /
por: Fernández García, David
Publicado: (2009)

The hieroglyphic stairway, ruins of Copan: report on explorations by the Museum
por: Gordon, George Byron, 1870-1927
Publicado: (1902)

Initial Real-World Experience with Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration
por: Leung, Ella H, et al.
Publicado: (2023)

One-Year Outcomes of Faricimab Treatment for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
por: Rush, Ryan B
Publicado: (2023)

Pharmacokinetics of the Port Delivery System with Ranibizumab in the Ladder Phase 2 Trial for Neovascular Age-Related Macular Degeneration
por: Wykoff, Charles C., et al.
Publicado: (2022)

Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set
por: Lotery, A, et al.
Publicado: (2017)

Stairway to the stars: the story of the world’s largest observatory
por: Parker, Barry
Publicado: (1994)

Short-Term Outcomes of Faricimab Treatment in Aflibercept-Refractory Eyes with Neovascular Age-Related Macular Degeneration
por: Kishi, Maya, et al.
Publicado: (2023)

Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial
por: Mori, Ryusaburo, et al.
Publicado: (2023)

Baseline characteristics associated with early visual acuity gains after ranibizumab treatment for retinal vein occlusion
por: Lloyd Clark, W., et al.
Publicado: (2019)

Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review
por: Liberski, Sławomir, et al.
Publicado: (2022)

Stairway to success: the complete blueprint for personal and professional achievement
por: Qubein, Nido R
Publicado: (1997)

Stairway to Heaven: A First-Person Account of Noesis
por: Singh, Swaran P.
Publicado: (2022)

Eligibility for faricimab in a real-world neovascular age-related macular degeneration population: a cross-sectional study
por: Jern, Iréne, et al.
Publicado: (2022)

Faricimab Effectively Resolves Intraretinal Fluid and Preserves Vision in Refractory, Recalcitrant, and Nonresponsive Neovascular Age-Related Macular Degeneration
por: Cheng, Anny M, et al.
Publicado: (2023)

New Therapies of Neovascular AMD beyond Anti-VEGF Injections
por: Gahn, Greggory M., et al.
Publicado: (2018)

Faricimab for Treatment-Resistant Diabetic Macular Edema
por: Rush, Ryan B, et al.
Publicado: (2022)

Clinical experience with fixed bimonthly aflibercept dosing in treatment-experienced patients with neovascular age-related macular degeneration
por: Khanani, Arshad M
Publicado: (2015)

Endophthalmitis rates among patients receiving intravitreal anti-VEGF injections: a USA claims analysis
por: Kiss, Szilárd, et al.
Publicado: (2018)

Single intravitreal ranibizumab for myopic choroidal neovascularization
por: Nor-Masniwati, Saidin, et al.
Publicado: (2011)

Ranibizumab in neovascular age-related macular degeneration
por: Eng, Kenneth T, et al.
Publicado: (2006)

An Immunological Stairway to Severe Tissue Complication Assembly in Bothrops atrox Snakebites
por: Ibiapina, Hiochelson Najibe Santos, et al.
Publicado: (2019)

Performing Economic Evaluation of Integrated Care: Highway to Hell or Stairway to Heaven?
por: Tsiachristas, Apostolos, et al.
Publicado: (2016)

Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis
por: Souied, Eric H., et al.
Publicado: (2016)

Visual and Anatomical Outcomes After Initial Intravitreal Faricimab Injection for Neovascular Age-Related Macular Degeneration in Patients with Prior Treatment History
por: Inoda, Satoru, et al.
Publicado: (2023)

Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Oedema: Lessons Learned from Registration Trials
por: Larsen, Helene O., et al.
Publicado: (2023)

Port delivery system with ranibizumab (Susvimo) recall- What does it mean to the retina specialists
por: Sharma, Ashish, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qvgfaoq192lignj48p0bdl7squ